Phase 3 Readout
RYTM: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of S
June 30, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 30, 2026
- Company
- RHYTHM PHARMACEUTICALS, INC. (RYTM)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout
Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of S
- Indication
- Obesity; Genetic Obesity